GENE - CHEMICAL INTERACTIONS REPORT
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
Object Symbol | Qualifier | Evidence | With | Reference | Source | Notes | Original Reference(s) | Parp1 | increases expression | EXP | | 6480464 | CTD | Lipopolysaccharides results in increased expression of PARP1 protein | PMID:24973090 | Parp1 | multiple interactions | EXP | | 6480464 | CTD | Sialic Acids inhibits the reaction [Lipopolysaccharides results in increased expression of PARP1 protein] | PMID:24973090 | Parp1 | increases expression | ISO | Parp1 (Mus musculus) | 6480464 | CTD | Lipopolysaccharides results in increased expression of PARP1 protein modified form | PMID:23170834 | Parp1 | multiple interactions | ISO | PARP1 (Homo sapiens) | 6480464 | CTD | 3,4-dihydro-5-(4-(1-piperidinyl)butoxy)-1(2H)-isoquinolinone inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of PARP1 protein]; [Lipopolysaccharides co-treated with IFNG protein] results in increased expression of PARP1 protein; Carnosine inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of PARP1 protein]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of PARP1 protein]; omega-N-Methylarginine inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of PARP1 protein]; Trehalose inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of PARP1 protein] | PMID:23011206 | Parp1 | multiple interactions | ISO | Parp1 (Mus musculus) | 6480464 | CTD | [[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein] which results in increased cleavage of PARP1 protein; [FXN gene mutant form results in increased susceptibility to Lipopolysaccharides] which results in increased expression of PARP1 protein; [triptolide co-treated with Lipopolysaccharides] results in increased expression of PARP1 protein modified form; benzyloxycarbonyl-valyl-alanyl-aspartyl-fluoromethane inhibits the reaction [[triptolide co-treated with Lipopolysaccharides] results in increased expression of PARP1 protein modified form]; gentiopicroside inhibits the reaction [[[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein] which results in increased cleavage of PARP1 protein]; notoginsenoside R1 inhibits the reaction [Lipopolysaccharides results in increased expression of PARP1 protein modified form]; PARP1 gene mutant form inhibits the reaction [Lipopolysaccharides affects the localization of and results in increased activity of RELA protein]; PARP1 gene mutant form inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; PARP1 protein affects the reaction [Lipopolysaccharides results in increased activity of MPO protein]; PARP1 protein affects the reaction [Lipopolysaccharides results in increased expression of CCL3 protein]; PARP1 protein affects the reaction [Lipopolysaccharides results in increased expression of CXCL2 protein]; PARP1 protein affects the reaction [Lipopolysaccharides results in increased expression of IL1B protein]; PARP1 protein affects the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; PARP1 protein affects the reaction [Lipopolysaccharides results in increased expression of TNF protein]; PARP1 protein affects the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein]; PARP1 protein affects the reaction [Lipopolysaccharides results in increased secretion of TNF protein] | PMID:11818323 PMID:17438151 PMID:20558151 PMID:23170834 PMID:26954031 PMID:27984176 PMID:30633930 | | ||||||||||||||||||||||
| Go Back to source page | Continue to Ontology report |